General Information of the m6A Target Gene (ID: M6ATAR00221)
Target Name Casein kinase II subunit alpha' (CSNK2A2)
Synonyms
CK II alpha'; CK2A2
    Click to Show/Hide
Gene Name CSNK2A2
Chromosomal Location 16q21
Family protein kinase superfamily; Ser/Thr protein kinase family; CK2 subfamily
Function
Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine. Regulates numerous cellular processes, such as cell cycle progression, apoptosis and transcription, as well as viral infection. May act as a regulatory node which integrates and coordinates numerous signals leading to an appropriate cellular response. During mitosis, functions as a component of the p53/TP53-dependent spindle assembly checkpoint (SAC) that maintains cyclin-B-CDK1 activity and G2 arrest in response to spindle damage. Also required for p53/TP53-mediated apoptosis, phosphorylating 'Ser-392' of p53/TP53 following UV irradiation. Can also negatively regulate apoptosis. Phosphorylates the caspases CASP9 and CASP2 and the apoptotic regulator NOL3. Phosphorylation protects CASP9 from cleavage and activation by CASP8, and inhibits the dimerization of CASP2 and activation of CASP8. Regulates transcription by direct phosphorylation of RNA polymerases I, II, III and IV. Also phosphorylates and regulates numerous transcription factors including NF-kappa-B, STAT1, CREB1, IRF1, IRF2, ATF1, SRF, MAX, JUN, FOS, MYC and MYB. Phosphorylates Hsp90 and its co-chaperones FKBP4 and CDC37, which is essential for chaperone function. Regulates Wnt signaling by phosphorylating CTNNB1 and the transcription factor LEF1. Acts as an ectokinase that phosphorylates several extracellular proteins. During viral infection, phosphorylates various proteins involved in the viral life cycles of EBV, HSV, HBV, HCV, HIV, CMV and HPV.
    Click to Show/Hide
Gene ID 1459
Uniprot ID
CSK22_HUMAN
HGNC ID
HGNC:2459
Ensembl Gene ID
ENSG00000070770
KEGG ID
hsa:1459
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
CSNK2A2 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Fat mass and obesity-associated protein (FTO) [ERASER]
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary In bladder cancer, the changes in m6A methylation level mainly appeared at 5' untranslated region (5' UTR) of MALAT1 and NOTCH1 transcripts, and at 3' UTR of Casein kinase II subunit alpha' (CSNK2A2) and ITGA6 transcripts, responding to the overexpression of FTO. SFPQ could influence the FTO-mediated m6A RNA demethylation, eventually affecting the gene expression.
Target Regulation Up regulation
Responsed Disease Bladder cancer ICD-11: 2C94
Pathway Response Notch signaling pathway hsa04330
Cell Process Cell proliferation
Cell invasion
Cell apoptosis
In-vitro Model HT-1197 Recurrent bladder carcinoma Homo sapiens CVCL_1291
HT-1376 Bladder carcinoma Homo sapiens CVCL_1292
In-vivo Model BALB/cnu/nu mice (4-5 weeks old) were used for the xenograft experiment. The mice were randomly divided into 2 groups (n = 6 for each group) and injected with 5 × 106 HT-1197 cells in control group or FTO plasmid group, respectively.
RNA demethylase ALKBH5 (ALKBH5) [ERASER]
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [2]
Response Summary knockdown of ALKBH5 promoted bladder cancer cell proliferation, migration, invasion, and decreased cisplatin chemosensitivity, ALKBH5 inhibited the progression and sensitized bladder cancer cells to cisplatin through a Casein kinase II subunit alpha' (CSNK2A2)-mediated glycolysis pathway in an m6A-dependent manner.
Target Regulation Down regulation
Responsed Disease Bladder cancer ICD-11: 2C94
Responsed Drug Cisplatin Approved
Pathway Response Metabolic pathways hsa01100
Glycolysis / Gluconeogenesis hsa00010)
Cell Process Glycolysis
In-vitro Model UM-UC-3 Bladder carcinoma Homo sapiens CVCL_1783
T24 Bladder carcinoma Homo sapiens CVCL_0554
SV-HUC-1 Normal Homo sapiens CVCL_3798
J82 Bladder carcinoma Homo sapiens CVCL_0359
253J Bladder carcinoma Homo sapiens CVCL_7935
5637 Bladder carcinoma Homo sapiens CVCL_0126
Bladder cancer [ICD-11: 2C94]
In total 2 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary In bladder cancer, the changes in m6A methylation level mainly appeared at 5' untranslated region (5' UTR) of MALAT1 and NOTCH1 transcripts, and at 3' UTR of Casein kinase II subunit alpha' (CSNK2A2) and ITGA6 transcripts, responding to the overexpression of FTO. SFPQ could influence the FTO-mediated m6A RNA demethylation, eventually affecting the gene expression.
Responsed Disease Bladder cancer [ICD-11: 2C94]
Target Regulator Fat mass and obesity-associated protein (FTO) ERASER
Target Regulation Up regulation
Pathway Response Notch signaling pathway hsa04330
Cell Process Cell proliferation
Cell invasion
Cell apoptosis
In-vitro Model HT-1197 Recurrent bladder carcinoma Homo sapiens CVCL_1291
HT-1376 Bladder carcinoma Homo sapiens CVCL_1292
In-vivo Model BALB/cnu/nu mice (4-5 weeks old) were used for the xenograft experiment. The mice were randomly divided into 2 groups (n = 6 for each group) and injected with 5 × 106 HT-1197 cells in control group or FTO plasmid group, respectively.
Experiment 2 Reporting the m6A-centered Disease Response [2]
Response Summary knockdown of ALKBH5 promoted bladder cancer cell proliferation, migration, invasion, and decreased cisplatin chemosensitivity, ALKBH5 inhibited the progression and sensitized bladder cancer cells to cisplatin through a Casein kinase II subunit alpha' (CSNK2A2)-mediated glycolysis pathway in an m6A-dependent manner.
Responsed Disease Bladder cancer [ICD-11: 2C94]
Target Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
Target Regulation Down regulation
Responsed Drug Cisplatin Approved
Pathway Response Metabolic pathways hsa01100
Glycolysis / Gluconeogenesis hsa00010)
Cell Process Glycolysis
In-vitro Model UM-UC-3 Bladder carcinoma Homo sapiens CVCL_1783
T24 Bladder carcinoma Homo sapiens CVCL_0554
SV-HUC-1 Normal Homo sapiens CVCL_3798
J82 Bladder carcinoma Homo sapiens CVCL_0359
253J Bladder carcinoma Homo sapiens CVCL_7935
5637 Bladder carcinoma Homo sapiens CVCL_0126
Cisplatin [Approved]
In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response [2]
Response Summary knockdown of ALKBH5 promoted bladder cancer cell proliferation, migration, invasion, and decreased cisplatin chemosensitivity, ALKBH5 inhibited the progression and sensitized bladder cancer cells to cisplatin through a Casein kinase II subunit alpha' (CSNK2A2)-mediated glycolysis pathway in an m6A-dependent manner.
Target Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
Target Regulation Down regulation
Responsed Disease Bladder cancer ICD-11: 2C94
Pathway Response Metabolic pathways hsa01100
Glycolysis / Gluconeogenesis hsa00010)
Cell Process Glycolysis
In-vitro Model UM-UC-3 Bladder carcinoma Homo sapiens CVCL_1783
T24 Bladder carcinoma Homo sapiens CVCL_0554
SV-HUC-1 Normal Homo sapiens CVCL_3798
J82 Bladder carcinoma Homo sapiens CVCL_0359
253J Bladder carcinoma Homo sapiens CVCL_7935
5637 Bladder carcinoma Homo sapiens CVCL_0126
References
Ref 1 The tumor-suppressive effects of alpha-ketoglutarate-dependent dioxygenase FTO via N6-methyladenosine RNA methylation on bladder cancer patients. Bioengineered. 2021 Dec;12(1):5323-5333. doi: 10.1080/21655979.2021.1964893.
Ref 2 ALKBH5 Inhibited Cell Proliferation and Sensitized Bladder Cancer Cells to Cisplatin by m6A-CK2Alpha-Mediated Glycolysis. Mol Ther Nucleic Acids. 2020 Oct 22;23:27-41. doi: 10.1016/j.omtn.2020.10.031. eCollection 2021 Mar 5.